CD274 and non-small cell lung carcinoma: EMPOWER-Lung 3 (NCT03409614), a multicenter, double-blind, randomized phase 3 trial, evaluated cemiplimab in combination with chemotherapy versus chemotherapy alone in patients with advanced NSCLC and any level of PD-L1 expression [14, 16].